<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02059512</url>
  </required_header>
  <id_info>
    <org_study_id>NBK-2901-AMNKM</org_study_id>
    <nct_id>NCT02059512</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease</brief_title>
  <acronym>TAMIS</acronym>
  <official_title>Influence of the Administration of Autologous Bone Marrow Mononuclear Cells for the Duration of Functioning Aorto-coronary Bypass Grafts in the Surgical Treatment of Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Petersburg State Pavlov Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study evaluate the effect of the method of administration of autologous&#xD;
      bone marrow mononuclear cells for the duration of of functioning aorto-coronary bypass grafts&#xD;
      in the surgical treatment of coronary heart disease, to assess the degree of effectiveness&#xD;
      depending on the method of transplantation (intramyocardial, intracoronary, combined).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Additional estimation of safety:&#xD;
&#xD;
        1. Assessment of EuroScore II.&#xD;
&#xD;
        2. Hospital Stay.&#xD;
&#xD;
        3. The duration of stay in the intensive care unit.&#xD;
&#xD;
        4. Restoration of cardiac rhythm at the end of the main stage of operation (defibrillation/&#xD;
           self-recovery).&#xD;
&#xD;
        5. The time of extracorporeal circulation.&#xD;
&#xD;
        6. Time of anoxia.&#xD;
&#xD;
        7. Volume abjointed (drainage) postoperative day 1, day 3&#xD;
&#xD;
        8. Troponin I, CPK-MB, Myoglobin at 1, 3 postoperative days.&#xD;
&#xD;
        9. Hb/ HCT/K+ at the end of cardiopulmonary bypass (CPB) and Hb/ HCT/K+/ ABC at the end of&#xD;
           the operation.&#xD;
&#xD;
       10. Assessment of the degree of manifestation of a systemic inflammatory reaction in the&#xD;
           postoperative period - leukocytes (Leu), CRP&#xD;
&#xD;
       11. Postoperative complications (hydrothorax, hydropericardium, arrhythmias, resternotomy).&#xD;
&#xD;
       12. Echocardiography at 7-14 days after surgery.&#xD;
&#xD;
      Estimation of efficiency:&#xD;
&#xD;
        1. Evaluation of systolic and diastolic myocardial function. Assessment of myocardial&#xD;
           perfusion and metabolism (before and after treatment) - Speckle tracking&#xD;
           echocardiography.&#xD;
&#xD;
        2. Patency of grafts within a specified time of treatment (angiography).&#xD;
&#xD;
        3. Dependence and duration of positive clinical effect on the amount of injected cell&#xD;
           material.&#xD;
&#xD;
        4. Evaluation of the quality of life (Minnesota questionnaire, Seattle questionnaire, SF-&#xD;
           36 questionnaire).&#xD;
&#xD;
        5. All-cause Mortality Associated With the Progression of Basic&#xD;
&#xD;
        6. Disease.Dynamics of the functional class of angina.&#xD;
&#xD;
        7. Dynamics of the functional class of heart failure.&#xD;
&#xD;
        8. Dynamics of test data with a 6-minute walk.&#xD;
&#xD;
      Predicting the results of treatment (the effect of a number of parameters):&#xD;
&#xD;
        1. Age.&#xD;
&#xD;
        2. Gender.&#xD;
&#xD;
        3. The body mass index.&#xD;
&#xD;
        4. Diabetes.&#xD;
&#xD;
        5. Smoking.&#xD;
&#xD;
        6. Family history of cardiovascular events.&#xD;
&#xD;
        7. Duration of ischemic heart disease.&#xD;
&#xD;
        8. Serum total cholesterol (+ fractions).&#xD;
&#xD;
        9. Leukocytosis and CRP level (initial level and rate of decrease in the postoperative&#xD;
           period).&#xD;
&#xD;
       10. The level of creatinine.&#xD;
&#xD;
       11. The presence / absence of extracardiac arteriopathy.&#xD;
&#xD;
       12. The intramyocardial or intracoronary injection of BM-MNCs.&#xD;
&#xD;
       13. Assessment of the bone marrow: the number of nucleated cells, CD34 +, CD133 +.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Potential participants in this study were all patients admitted for planned coronary artery bypass grafting under extracorporeal circulation and who, according to angiographic examination, had 3 or more stenotic coronary arteries. The final decision on the inclusion of each individual patient in this study was determined taking into account the inclusion criteria. The study was conducted according to the approved protocol as a randomized, blind, placebo controlled.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Randomization into three observation groups was carried out according to the table of random numbers.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the Initial Risk of Surgery (EuroScore II).</measure>
    <time_frame>Before CABG surgery at baseline.</time_frame>
    <description>EuroScoreII is intended to assess the risk of adverse outcome of coronary artery bypass grafting. Assessment factors: age, sex, serum creatinine, extracardiac artery disease, chronic lung disease, severe neurological disorders, previous cardiac surgery, previous myocardial infarction, left ventricular dysfunction, diabetes mellitus, pulmonary hypertension, IV class of angina severity, active endocarditis, unstable angina, surgery, critical condition of the patient before surgery, type of surgery. The higher the percentage, the higher the risk of surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Hospital Stay. Length of Stay in the Intensive Care Unit.</measure>
    <time_frame>Primary hospitalization for planned CABG.</time_frame>
    <description>The results were obtained from the analysis of primary data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Severity of the Systemic Inflammatory Response in the Postoperative Period (Leukocytosis).</measure>
    <time_frame>The parameters were evaluated initially at baseline in the postoperative period - an interval of 0-6 hours, 12-18 hours, 18-24 hours, 48 hours, 72 hours, 96 hours, 7 days and 14 days.</time_frame>
    <description>Assessment of the severity of the systemic inflammatory response during hospital stay after surgery. Assessment of the level of inflammation by the severity of an increase in leukocytes (leukocytosis).&#xD;
Leukocytosis - an increase in the number of leukocytes per unit volume of blood. The norm of leukocytes in the blood is 5.5-8.810^9 /l. For adults, leukocytosis is considered to be an increase in the number of leukocytes in the blood of more than 9.0*10^9 / l In the statistical analysis, the grouping of indicators in the indicated intervals was used, in view of the individual characteristics of the course of the postoperative period in each case.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the Degree of General Inflammatory Response (C-reactive Protein (CRP)),</measure>
    <time_frame>Initial data, control point in the interval 4-6 days of the postoperative period, control point in the interval 12-14 days of the postoperative period.</time_frame>
    <description>Results of dynamic control of laboratory parameters of CRP. C-reactive protein. This fraction of plasma proteins increases in the presence of an inflammatory process in the body. It is synthesized in response to the ingestion of toxins of pathological microorganisms into the bloodstream and neutralizes them by binding them. In addition, it appears when the body's own cells are destroyed in the event of necrosis, tumor disintegration or extensive trauma, inactivating the resulting products. In addition to eliminating toxins, CRP triggers a cascade of immune responses aimed at eliminating pathologically altered structures.&#xD;
Normally absent (or less than 0.4 mg / l). In the statistical analysis, the grouping of indicators in the indicated intervals was used, in view of the individual characteristics of the course of the postoperative period in each case.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Volume of Discharge Through the Drains in the Early Postoperative Period.</measure>
    <time_frame>Evaluation of these data - for the time spent in the intensive care unit before removing the drains.</time_frame>
    <description>A daily assessment of the discharge by drainage before removal was carried out. It was carried out to assess the possible development of an excessive inflammatory reaction (polyserositis phenomena) in response to the transplantation of autologous bone marrow mononuclear cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dynamics of Markers of Myocardial Damage (Troponin I, Myoglobin).</measure>
    <time_frame>1 and 3 days of the postoperative period.</time_frame>
    <description>Assessment of the severity of the period of ischemia / reperfusion. And the effect of autologous bone marrow mononuclear cells transplantation on these indicators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dynamics of Markers of Myocardial Damage (Creatine Phosphokinase Fraction MB (CPK-MB)).</measure>
    <time_frame>1 and 3 days of the postoperative period.</time_frame>
    <description>Assessment of the severity of the period of ischemia / reperfusion. And the effect of autologous bone marrow mononuclear cells transplantation on these indicators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraoperative Assessment of Homeostasis (Hemoglobin (Hb).</measure>
    <time_frame>Intraoperative data.</time_frame>
    <description>These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraoperative Assessment of Homeostasis (Hematocrit (HCT)).</measure>
    <time_frame>Intraoperative data.</time_frame>
    <description>These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraoperative Assessment of Homeostasis (К+).</measure>
    <time_frame>Intraoperative data.</time_frame>
    <description>These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiopulmonary Bypass Time.</measure>
    <time_frame>Intraoperative data.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Aortic Clamping (Anoxia).</measure>
    <time_frame>Intraoperative data.</time_frame>
    <description>Estimation of the time from the moment the clamp is applied to the aorta (complete clamping of the aorta) to the removal of the clamp from the aorta.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Complications in the Postoperative Period. Additional Estimation of Safety.</measure>
    <time_frame>Postoperative period.</time_frame>
    <description>The presence of complications in the postoperative period (Hydrothorax, Hydropericardium, Cardiac arrhythmias - atrial fibrillation / atrial flutter).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction - Echocardiography - Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment. Additional Estimation of Safety.</measure>
    <time_frame>7-14 days of the postoperative period</time_frame>
    <description>Evaluation of myocardial contractility according to echocardiography, in particular the left ventricular ejection fraction, was carried out within 7-14 days of the postoperative period, depending on the patient's clinical condition, as well as the maximum degree of information content of this study. The lower the indicator, the worse the prognosis of an unfavorable outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment - Echocardiography (Size of the Left Ventricle - Index). Additional Estimation of Safety.</measure>
    <time_frame>7-14 days after surgery</time_frame>
    <description>Assessment of myocardial contractility according to echocardiography, in particular the size of the left ventricle - its index, was carried out within 7-14 days of the postoperative period, depending on the clinical condition of the patient, as well as on the maximum information content of this study. The higher the indicator (left ventricular size - index), the worse the prognosis of an unfavorable outcome.&#xD;
The index is used as an indicator of payment to obtain a more reliable result (taking into account the individual characteristics of each patient).&#xD;
index - left ventricular size (mm.)/ body mass index (kg/m^2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of the Left Ventricle - Index - Echocardiography. Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment. Additional Estimation of Safety.</measure>
    <time_frame>7-14 days after surgery</time_frame>
    <description>Evaluation of myocardial contractility according to echocardiography, in particular volume of the left ventricle - index was carried out within 7-14 days of the postoperative period, depending on the patient's clinical condition, as well as the maximum degree of information content of this study. The greater the figure (volume of the left ventricle - index), the worse the prognosis of adverse outcome.&#xD;
The index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).&#xD;
index - volume of the left ventricle (ml.)/ body mass index (kg / m^2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Restoration of the Heart Rate After the Completion of the Main Stage of the Surgical Intervention. Additional Estimation of Safety.</measure>
    <time_frame>Upon completion of the main stage of surgery.</time_frame>
    <description>The need to perform defibrillation to restore sinus rhythm, at the end of the main stage of surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality Associated With the Progression of Basic Disease.</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>The total number of deaths - in the primary hospitalization and during the observation period of 12 months after surgical treatment - deaths associated with the progression of the initial disease.&#xD;
The complication rate for CABG operations is 30±10%. According to n1=kn2; n1 sample size, in the control. In group 0, k=2/3 times more than in group 1 and group 2. The difference between the test and control frequencies is ε=p1-p2. Accordingly, with p1 = 0.2; p2=0.4, δ= 0.1; n1=49.5, n2=33. The result is group 0 - 36, group 1 and 2 - 25+25 = 50. The null hypothesis of complication rate δ.All patients included in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life. Evaluation of the Quality of Life (Minnesota Questionnaire (MHFLQ), Seattle Questionnaire (SAQ), SF-36 Questionnaire). Estimation of Efficiency.</measure>
    <time_frame>At baseline and after one year.</time_frame>
    <description>The SF-36 questionnaire. The indicators of each scale vary between 0 and 100, where 100 represents total health. The results are presented in the form of scores on 8 scales, compiled in such a way that a higher score indicates a higher level of quality of life.MHFLQ - for patients with heart failure.The specified questionnaire consists of 21 questions. To answer each question, a scale of 6 points from the minimum intensity of certain symptoms to the maximum is used. The assessment is based on the sum of points, where the maximum number of points - 105 corresponds to the patient's worst condition. The lowest score 0 points is the best clinical condition of the patient. SAQ consists of 19 questions about the patient's condition, which are divided into the following 5 scales. The quality of life for each of the five scales under consideration is measured in percent, with 0% corresponding to the worst quality of life, and 100% to the best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the Functional Class of Exertional Angina at 12 Months After Surgical Treatment.</measure>
    <time_frame>up to 12 months</time_frame>
    <description>functional class - The usual load does not cause changes in the state of health. Painful attacks occur against the background of excessive loads - after climbing several flights of stairs, while walking fast.&#xD;
functional class - Pain attacks when walking more than 500 meters, when climbing stairs more than one floor.&#xD;
functional class - The patient does not tolerate minimal physical activity. An attack occurs when walking a distance of 50-100 meters. Climbing stairs is difficult.&#xD;
functional class - Activity is significantly limited. Angina pectoris manifests itself when performing minimal actions, including at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of the Functional Class of Heart Failure (NYHA). Estimation of Efficiency.</measure>
    <time_frame>Assessment of the dynamics at 12 months after treatment.</time_frame>
    <description>functional class - There is no limitation of a person's physical activity, shortness of breath manifests itself when going above the third floor.&#xD;
functional class - slight limitation of activity, palpitations, shortness of breath, fatigue occur during normal physical activity and more.&#xD;
functional class - Symptoms occur with the smallest physical activity, resulting in a significant decrease in activity. At rest, clinical manifestations are not observed.&#xD;
The smaller the functional class, the better the quality of human life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Left Ventricular Ejection Fraction 12 Months After Treatment.</measure>
    <time_frame>12 months after treatment.</time_frame>
    <description>According to echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of the Index of Linear Parameters of the Left Ventricle 12 Months After the Treatment. Estimation of Efficiency.</measure>
    <time_frame>12 months after the treatment.</time_frame>
    <description>Evaluation of myocardial contractility according to echocardiography, in particular the size of the left ventricle - the index was carried out 12 months after CABG. The higher the indicator (left ventricular size - index), the worse the prognosis of an unfavorable outcome.&#xD;
The index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).&#xD;
index - size of the left ventricle (mm.)/ body mass index (kg/m^2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of the Index of Volumetric Parameters of the Left Ventricle 12 Months After the Treatment. Estimation of Efficiency.</measure>
    <time_frame>12 Months After the Treatment</time_frame>
    <description>Evaluation of myocardial contractility according to echocardiography, in particular the volume of the left ventricle - the index was carried out 12 months after CABG. The higher the indicator (left ventricular volume - index), the worse the prognosis of an unfavorable outcome.&#xD;
The index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).&#xD;
index - volume of the left ventricle (mm.)/ body mass index (kg/m^2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Left Ventricular Diastolic Function - Peak E of Transmitral Flow and Peak А of Transmitral Flow 12 Months After Treatment.</measure>
    <time_frame>12 months after treatment.</time_frame>
    <description>Evaluation of left ventricular diastolic function (echocardiography). The peak velocity E reflects the pressure gradient between the LA and LV in early diastole, and it is affected by preload and disturbance LV relaxation The speed of peak A, which forms at the end diastole, influences LV compliance and contractility left atrium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Left Ventricular Diastolic Function E/A - 12 Months After Treatment.</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>The ratio of the transmitral flow, wave E (ejection wave / left ventricular contraction) to wave A (ejection wave / left atrial contraction). The norm is 0.75-1.5 Less than 0.75 violation of relaxation, more than 1.5 restrictive type of diastolic dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Left Ventricular Diastolic Function - DT and IVRT 12 Months After Treatment.</measure>
    <time_frame>12 Months After Treatment.</time_frame>
    <description>Echocardiographic data ( DT (Half-time of wave E), time of isovolumic relaxation of the left ventricle (IVRT).&#xD;
DT (Half-time of wave E). The DT time index reflects the relaxation process LV, LV diastolic pressure after mitral valve opening, and LV compliance. 150-200 ms - normal; &gt; 200 ms - violation of relaxation; 150-200 ms - pseudonormal type of left ventricular filling; &lt;150 ms - restrictive type of diastolic dysfunction IVRT (time of isovolumic relaxation of the left ventricl.) &lt;100 ms - normal; &gt; 100 ms - violation of relaxation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance Traveled in the 6-minute Walk Test. Test Results With 6 Minute Walk</measure>
    <time_frame>initially and after 12 months</time_frame>
    <description>The dynamic of the number of meters walked according to the 6-minutes walk test (6MWD) in the observation groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Functioning Grafts 12 Months After CABG. Patency of Grafts Within a Specified Time of Treatment (Angiography).</measure>
    <time_frame>up to 12 months</time_frame>
    <description>According to the angiographic study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the Effect of Left Ventricular Diastolic Dysfunction on the Patency of the Grafts.</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Echocardiographic data.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The Volume of Cellular Material (Cytosis).</measure>
    <time_frame>Initial data at the time of collection of bone marrow cells.</time_frame>
    <description>Dependence and Duration of Positive Clinical Effect on the Amount of Injected Cell Material (cytosis).</description>
  </other_outcome>
  <other_outcome>
    <measure>The Amount of Cell Material (Percentage).</measure>
    <time_frame>Initial data at the time of collection of bone marrow cells.</time_frame>
    <description>Dependence and duration of positive clinical effect on the amount of injected cell material (Mononuclear fraction %, CD34+ %, CD133+ %).&#xD;
Assessment - mononuclear fraction, CD 34 +, CD 133+ according to flow cytometry data.</description>
  </other_outcome>
  <other_outcome>
    <measure>Smoking as a Factor That Negatively Affects the Results of the Test With a 6-minute Walk in Dynamics.</measure>
    <time_frame>12 months after treatment.</time_frame>
    <description>The distance covered (in meters) was compared with the proper value depending on age (years), height (cm), weight (kg), body mass index (BMI). The due values (6MWD (i)) were calculated using the following formulas: For men: 6МWD (i) = 7.57 × height - 5.02 × age - 1.76 × weight - 309 or 6MWD (i) = 1140 - 5.61 × BMI - 6.94 × age. For women:&#xD;
6МWD (i) = 2.11 × height - 2.29 × weight - 5.78 × age + 667 Or 6МWD (i) = 1017 - 6.24 × BMI - 5.83 × age. This difference at baseline is reported as distance walked for smokers minus non-smokers.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Bone Marrow Cells</condition>
  <condition>Coronary Artery Bypass Grafting (CABG)</condition>
  <condition>Heart Failure, Diastolic</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramyocardial administration of autologous bone marrow mononuclear cells during the operation coronary artery bypass grafting 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 0</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD during the operation coronary artery bypass grafting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells during coronary artery bypass grafting intramyocardial 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Group 1</intervention_name>
    <description>Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>CABG with intramyocardial administration of ABMMC.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Group 0</intervention_name>
    <description>Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
    <arm_group_label>Group 0</arm_group_label>
    <other_name>CABG with administration of 0.9 % sodium chlorid.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Group 2</intervention_name>
    <description>Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>CABG with intramyocardial and intracoronary administration of ABMMC.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women from 18 to 80 years&#xD;
&#xD;
          -  Patients with angina pectoris III-IV functional class&#xD;
&#xD;
          -  According to angiographic examination, the presence of 3 or more stenotic coronary&#xD;
             arteries&#xD;
&#xD;
          -  Aorto-coronary bypass surgery under cardiopulmonary bypass&#xD;
&#xD;
          -  Patients signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intolerance of heparin and HES.&#xD;
&#xD;
          -  Hypothyroidism and hyperthyroidism.&#xD;
&#xD;
          -  Associated pathology with a projected lifespan limitation to 3 years.&#xD;
&#xD;
          -  infection diseases&#xD;
&#xD;
          -  Simultaneous participation in another study.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Severe mental disorder.&#xD;
&#xD;
          -  Refusal of a patient to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir V Komok, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Pavlov State Medical University of St. Petersburg.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://journal.transpl.ru/vtio/article/view/1027</url>
    <description>Assessment of safety of additional transplantation of autologous bone marrow mononuclear cells in the combined treatment of coronary heart disease. Results from a randomized, blind, placebo-controlled trial (TAMIS).</description>
  </link>
  <link>
    <url>https://journal.transpl.ru/vtio/article/view/1106</url>
    <description>Evaluation of the effectiveness of combined treatment of coronary heart disease - coronary artery bypass grafting, transplantation of autologous bone marrow mononuclear cells: a randomized, double-blind, placebo-controlled study.</description>
  </link>
  <reference>
    <citation>Komok V.V., Bunenkov N.S., Beliy S.A., Pizin V.M., Kondratev V.M., Dulaev А.V., Lukashenko V.I., Kobak A.E., Maksimova T.S., Sergienko I.P., Parusova E.V., Smirnova L.A., Babenko E.V., Afanasev B.V., Nemkov A.S., Khubulava G.G. Assessment of safety of additional transplantation of autologous bone marrow mononuclear cells in the combined treatment of coronary heart disease. Results from a randomized, blind, placebo-controlled trial (TAMIS). Russian Journal of Transplantology and Artificial Organs. 2019;21(2):112-120. (In Russ.) https://doi.org/10.15825/1995-1191-2019-2-112-120</citation>
  </reference>
  <reference>
    <citation>Komok V.V., Bunenkov N.S., Beliy S.A., Pizin V.M., Kondratev V.M., Dulaev A.V., Kobak A.E., Maksimova T.S., Sergienko I.P., Parusova E.V., Smirnova L.A., Babenko E.V., Afanasev B.V., Nemkov A.S., Khubulava G.G. Evaluation of the effectiveness of combined treatment of coronary heart disease - coronary artery bypass grafting, transplantation of autologous bone marrow mononuclear cells: a randomized, double-blind, placebo-controlled study. Russian Journal of Transplantology and Artificial Organs. 2019;21(4):54-66. https://doi.org/10.15825/1995-1191-2019-4-54-66</citation>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 1, 2014</study_first_submitted>
  <study_first_submitted_qc>February 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2014</study_first_posted>
  <results_first_submitted>March 27, 2018</results_first_submitted>
  <results_first_submitted_qc>May 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 24, 2021</results_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic heart disease</keyword>
  <keyword>bone marrow cells</keyword>
  <keyword>coronary artery bypass grafting (CABG)</keyword>
  <keyword>reperfusion injury</keyword>
  <keyword>myocardial dysfunction, diastolic</keyword>
  <keyword>Heart Failure, Diastolic</keyword>
  <keyword>transplantation of autologous mononuclear cells</keyword>
  <keyword>intramyocardial administration</keyword>
  <keyword>intracoronary administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potential participants in the study were all patients referred to the clinic for surgical treatment of coronary artery disease.</recruitment_details>
      <pre_assignment_details>The study included patients admitted for routine coronary artery bypass grafting under cardiopulmonary bypass, and having, according to the angiographic studies, 3 or more of stenosed coronary arteries. Patients met the inclusion criteria and signed an informed voluntary consent.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intramyocardial Administration 0.9 % NaCl (Sodium Chloride) - Group 0</title>
          <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
        </group>
        <group group_id="P2">
          <title>Intramyocardial Administration Autologous Bone Marrow Stem Cells - Group 1</title>
          <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
        </group>
        <group group_id="P3">
          <title>Intramyocardial and Intracoronary Administration Autologous Bone Marrow Stem Cells - Group 2</title>
          <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study included patients admitted for coronary artery bypass grafting. Patients met the inclusion criteria and signed an informed consent.&#xD;
In the &quot;results&quot; section, data are provided for repeated examinations of patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Intramyocardial Administration 0.9 % NaCl (Sodium Chloride) - Group 0</title>
          <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
        </group>
        <group group_id="B2">
          <title>Intramyocardial Administration Autologous Bone Marrow Stem Cells - Group 1</title>
          <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
        </group>
        <group group_id="B3">
          <title>Intramyocardial and Intracoronary Administration Autologous Bone Marrow Stem Cells - Group 2</title>
          <description>Сoronary artery bypass grafting with intramyocardial ( 0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow mononuclear cells.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="8"/>
                    <measurement group_id="B2" value="61.7" spread="6.8"/>
                    <measurement group_id="B3" value="59.5" spread="5.4"/>
                    <measurement group_id="B4" value="60.9" spread="6.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Gender sign: Female, Male</description>
          <population>The analysis of the final statistics was made at the time the studies were completed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>North-West Russia:Novgorod region, Leningrad region, Pskov region.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>BMI (body mass index) = weit (kg)/(height (m))^2 Norm (18.5-25); 1-overweight (25-30); I degree of obesity (30-35); II degree of obesity (35-40); III degree of obesity (40 and&gt;).</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="3.59"/>
                    <measurement group_id="B2" value="28.05" spread="4.46"/>
                    <measurement group_id="B3" value="28.09" spread="3.57"/>
                    <measurement group_id="B4" value="28.3" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <description>According to laboratory data - compensated (diet, drug therapy, insulin).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertonic desease (stage).</title>
          <description>2 stage - Blood pressure ranges from 160/100 to 179/109 mm Hg. There are signs of damage to the heart, retina and kidneys, which can only be detected by instrumental or laboratory examination methods. There are no subjective symptoms of their defeat.&#xD;
3 stage - Blood pressure is 180/110 mm Hg. and higher. There are objective signs and subjective symptoms of the heart, the brain, retina, kidney, or blood vessels.&#xD;
Stage 2 is associated with a lower risk of adverse cardiovascular events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>2 stage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 stage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arterial hypertension (degree)</title>
          <description>degree - Blood pressure ranges from 140/90 to 159/99 mm. Hg&#xD;
degree - Blood pressure ranges from 160/100 to 179/109 mm Hg.&#xD;
degree - Blood pressure is 180/110 mm Hg. and higher.&#xD;
Degree 1 and 2 is associated with a lower risk of adverse cardiovascular events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peripheral arteriopathy.</title>
          <description>The presence of peripheral arteriopathy (hemodynamically significant stenosis in the carotid arteries, arteries of the lower extremities).&#xD;
According to ultrasound, angiographic research methods: carotid arteries, lower limb arteries.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Acute myocardial infarction transferred in history (number).</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>1 acute myocardial infarctions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 acute myocardial infarctions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 acute myocardial infarctions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking.</title>
          <description>Active smoking at the time of hospitalization for routine CABG.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family history of cardiovascular disease.</title>
          <description>Family history of cardiovascular disease: hypertension, arterial hypertension, AMI, stroke, the presence of peripheral arteriopathy requiring medical intervention.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Debut of ischemic heart disease (months).</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.9" spread="70.9"/>
                    <measurement group_id="B2" value="62.9" spread="79.2"/>
                    <measurement group_id="B3" value="76.9" spread="59.4"/>
                    <measurement group_id="B4" value="69.3" spread="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Debut of ischemic heart disease.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Debut of ischemic heart disease up to 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Debut of ischemic heart disease 6-10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Debut of ischemic heart disease over 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angina pectoris (functional class).</title>
          <description>2 functional class - Pain attacks when walking more than 500 meters, when climbing stairs more than one floor.&#xD;
3 functional class. Attacks when walking on level ground at 100-500 meters, when climbing stairs one floor.&#xD;
4 functional class. Seizures when walking on level ground at a distance of less than 100 meters, and when at rest.&#xD;
Painless myocardial ischemia is characterized by changes in myocardial blood supply without pain.&#xD;
The lower the functional class of angina pectoris, the better the quality of life.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>2 functional class</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 functional class</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 functional class</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>painless ischemia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart failure (functional class NYHA).</title>
          <description>functional class - There is no limitation of a person's physical activity, shortness of breath manifests itself when going above the third floor.&#xD;
functional class - slight limitation of activity, palpitations, shortness of breath, fatigue occur during normal physical activity and more.&#xD;
functional class - Symptoms occur with the smallest physical activity, resulting in a significant decrease in activity. At rest, clinical manifestations are not observed.&#xD;
The smaller the functional class, the better the quality of human life.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1 functional class</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 functional class</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 functional class</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total holesterol (mmol/l).</title>
          <description>The data at the time of hospitalization for routine CABG.</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.49" spread="1.08"/>
                    <measurement group_id="B2" value="4.5" spread="1.24"/>
                    <measurement group_id="B3" value="4.6" spread="1.49"/>
                    <measurement group_id="B4" value="4.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Very loud density lipoprotein (mmol/l).</title>
          <description>The data at the time of hospitalization for routine CABG.</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.96" spread="0.35"/>
                    <measurement group_id="B2" value="0.94" spread="0.5"/>
                    <measurement group_id="B3" value="0.77" spread="0.3"/>
                    <measurement group_id="B4" value="0.95" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High density lipoproteins (mmol/l).</title>
          <description>The data at the time of hospitalization for routine CABG.</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" spread="0.89"/>
                    <measurement group_id="B2" value="2.58" spread="1.05"/>
                    <measurement group_id="B3" value="2.7" spread="1.26"/>
                    <measurement group_id="B4" value="2.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Loud density lipoproteins (mmol/l).</title>
          <description>The data at the time of hospitalization for routine CABG.</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.98" spread="0.31"/>
                    <measurement group_id="B2" value="1.16" spread="0.37"/>
                    <measurement group_id="B3" value="1.13" spread="0.29"/>
                    <measurement group_id="B4" value="1.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglyceride (mmol/l).</title>
          <description>The data at the time of hospitalization for routine CABG.</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.04" spread="0.68"/>
                    <measurement group_id="B2" value="1.69" spread="0.72"/>
                    <measurement group_id="B3" value="1.63" spread="0.62"/>
                    <measurement group_id="B4" value="1.9" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atherogenic coefficient.</title>
          <description>The data at the time of hospitalization for routine CABG. Atherogenic Coefficient (AC) is a predictor of the risk of coronary artery disease and is calculated as {(Total Cholesterol - HDLc)/HDLc}.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.07" spread="1.32"/>
                    <measurement group_id="B2" value="3.27" spread="1.9"/>
                    <measurement group_id="B3" value="4.5" spread="5.2"/>
                    <measurement group_id="B4" value="4.08" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine (mmol / l).</title>
          <description>The data at the time of hospitalization for routine CABG.</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.09" spread="0.02"/>
                    <measurement group_id="B2" value="0.09" spread="0.02"/>
                    <measurement group_id="B3" value="0.08" spread="0.02"/>
                    <measurement group_id="B4" value="0.09" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-reactive protein (mg/l).</title>
          <description>The data at the time of hospitalization for routine CABG.</description>
          <units>mg/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.9" spread="11.07"/>
                    <measurement group_id="B2" value="2.56" spread="1.96"/>
                    <measurement group_id="B3" value="5.3" spread="5.38"/>
                    <measurement group_id="B4" value="4.9" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glomerular filtration rate (ml/min/1.73 m^2) (assessment of renal function).</title>
          <description>The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration Formula):scale was used to assess renal function. The degree of renal dysfunction was assessed according to https://www.kidney.org/professionals/explore-your-knowledge/how-to-classify-ckd The standards are as follows: Category G1 ≥90 ml/min/1.73 m^2 (Normal or high); G2 - 60-89 ml/min/1.73 m^2 (Mildly decreased); G3a - 45-59 ml/min/1.73 m^2 (Mildly to moderately decreased); G3b - 30-44 ml/min/1.73 m^2 (Moderately to severely decreased); G4 15-29 ml/min/1.73 m^2 (Severely decreased); G 5 &lt;15 ml/min/1.73 m^2 (Kidney failure).</description>
          <units>ml/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.89" spread="15.8"/>
                    <measurement group_id="B2" value="77.6" spread="16.03"/>
                    <measurement group_id="B3" value="84.2" spread="17.26"/>
                    <measurement group_id="B4" value="77.9" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EuroScore II</title>
          <description>EuroScoreII is designed to assess the risk of adverse outcome in coronary artery bypass grafting. Assessment factors: age, gender, serum creatinine, extracardiac artery disease, chronic lung disease, severe neurological disorders, previous cardiac surgery, previous myocardial infarction, left ventricular dysfunction, diabetes mellitus, pulmonary hypertension, grade IV angina pectoris, active endocarditis, unstable angina pectoris, surgery, critical condition of the patient before surgery, type of surgery. The higher the score, the higher the risk of an adverse outcome.</description>
          <units>percentage of risk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" spread="0.68"/>
                    <measurement group_id="B2" value="1.07" spread="0.47"/>
                    <measurement group_id="B3" value="1.02" spread="0.4"/>
                    <measurement group_id="B4" value="1.15" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SYNTAX Score</title>
          <description>The SYNTAX Score Calculator is a scale developed in connection with the SYNTAX study The scale includes an assessment of the nature of the anatomical structure and atherosclerotic lesions of the coronary arteries. Each factor has a certain score. Based on the summation of the scores, the risk stratification is assessed. The following risk groups have been identified. Low-risk group with a score of 0-22, medium-risk group 23-32 points, high-risk group&gt; 32 points. http://www.syntaxscore.com/calculator/syntaxscore/frameset.htm</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.7" spread="7.0"/>
                    <measurement group_id="B2" value="26.8" spread="6.0"/>
                    <measurement group_id="B3" value="26.4" spread="7.3"/>
                    <measurement group_id="B4" value="26.7" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nitrates.</title>
          <description>Number participants who were receiving Nitrates treatment. Basic therapy for hospitalization for planned CABG.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diuretics.</title>
          <description>Number participants who were receiving Diuretics treatment. Basic therapy for hospitalization for planned CABG.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angiotensin converting enzyme inhibitors.</title>
          <description>Number participants who were receiving Angiotensin converting enzyme inhibitors treatment. Basic therapy for hospitalization for planned CABG.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angiotensin receptor antagonists.</title>
          <description>Number participants who were receiving Angiotensin receptor antagonists treatment.Basic therapy for hospitalization for planned CABG.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>β-blockers.</title>
          <description>Number participants who were receiving β-blockers treatment.Basic therapy for hospitalization for planned CABG.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antagonists СА - calcium tubules antagonists.</title>
          <description>Number participants who were receiving Antagonists СА - calcium tubules antagonists treatment. Basic therapy for hospitalization for planned CABG.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antiplatelet agents.</title>
          <description>Number participants who were receiving Antiplatelet agent treatment.Basic therapy for hospitalization for planned CABG.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anticoagulants.</title>
          <description>Number participants who were receiving Anticoagulants treatment.Basic therapy for hospitalization for planned CABG.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Statins.</title>
          <description>Number participants who were receiving Statins treatment. Basic therapy for hospitalization for planned CABG.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Echocardiography - 1. Lvd ind. Lvs ind. LAind.</title>
          <description>The data at the time of hospitalization for routine CABG. Indicators of size of the left chambers of the heart. Lvd ind. - left ventricular end-diastolic size index; Lvs ind. - left ventricular end-systolic size index; LA ind. - left atrial index.&#xD;
The greater figure (size of the left ventricle - index), worse the prognosis of adverse outcome.The index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).&#xD;
index - size of the left ventricle/ body mass index (kg / m^2).</description>
          <units>mm/ m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Lvd ind.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" spread="0.39"/>
                    <measurement group_id="B2" value="2.98" spread="0.5"/>
                    <measurement group_id="B3" value="2.8" spread="0.2"/>
                    <measurement group_id="B4" value="2.8" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lvs ind.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="0.42"/>
                    <measurement group_id="B2" value="2.1" spread="0.5"/>
                    <measurement group_id="B3" value="1.9" spread="0.4"/>
                    <measurement group_id="B4" value="1.9" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LAind.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="0.3"/>
                    <measurement group_id="B2" value="2.2" spread="0.3"/>
                    <measurement group_id="B3" value="2.1" spread="0.2"/>
                    <measurement group_id="B4" value="2.2" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Echocardiography - 2. LVEDV MOD BP ind. LVESV MOD BP ind.</title>
          <description>The data at the time of hospitalization for routine CABG. Volume indices of left heart chambers.&#xD;
LVEDV MOD BP ind. - left ventricular end-diastolic volume index. LVESV MOD BP ind. - left ventricular end-systolic volume index.&#xD;
The greater figure (size of the left ventricle - index), worse the prognosis of adverse outcome.The index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).&#xD;
index - size of the left ventricle/ body mass index (kg / m^2).</description>
          <units>ml/ m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>LVEDV MOD BP ind.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="20.7"/>
                    <measurement group_id="B2" value="73" spread="36.1"/>
                    <measurement group_id="B3" value="73.2" spread="29.9"/>
                    <measurement group_id="B4" value="62.7" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVESV MOD BP ind.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.6" spread="14.8"/>
                    <measurement group_id="B2" value="32.4" spread="27.9"/>
                    <measurement group_id="B3" value="31.9" spread="22.3"/>
                    <measurement group_id="B4" value="27.9" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Echocardiography - 3. LVEF (Simpson) - left ventricular ejection fraction.</title>
          <description>The data at the time of hospitalization for routine CABG. Assessment of the contractility of the left ventricular myocardium (systolic function)</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="7.4"/>
                    <measurement group_id="B2" value="56.6" spread="10.2"/>
                    <measurement group_id="B3" value="59.3" spread="11.1"/>
                    <measurement group_id="B4" value="59.8" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Echocardiography - 4. Left ventricular diastolic function - 1.</title>
          <description>Evaluation of left ventricular diastolic function (echocardiography). The peak velocity E reflects the pressure gradient between the LA and LV in early diastole, and it is affected by preload and disturbance LV relaxation The speed of peak A, which forms at the end diastole, influences LV compliance and contractility left atrium.</description>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Peak E of transmitral flow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.7" spread="0.2"/>
                    <measurement group_id="B2" value="0.6" spread="0.1"/>
                    <measurement group_id="B3" value="0.7" spread="0.2"/>
                    <measurement group_id="B4" value="0.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak A of transmitral flow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.8" spread="0.2"/>
                    <measurement group_id="B2" value="0.8" spread="0.2"/>
                    <measurement group_id="B3" value="0.7" spread="0.2"/>
                    <measurement group_id="B4" value="0.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Echocardiography - 5. Left ventricular diastolic function - 2 (E/A).</title>
          <description>The ratio of the transmitral flow, wave E (ejection wave / left ventricular contraction) to wave A (ejection wave / left atrial contraction). The norm is 0.75-1.5 Less than 0.75 violation of relaxation, more than 1.5 restrictive type of diastolic dysfunction.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.9" spread="0.4"/>
                    <measurement group_id="B2" value="0.9" spread="0.5"/>
                    <measurement group_id="B3" value="0.9" spread="0.5"/>
                    <measurement group_id="B4" value="0.9" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Echocardiography - 6. Left ventricular diastolic function - 3 (DT, IVRT).</title>
          <description>Assessment of left ventricular diastolic function. The data at the time of hospitalization for routine CABG. DT (Half-time of wave E). The DT time index reflects the relaxation process LV, LV diastolic pressure after mitral valve opening, and LV compliance. 150-200 ms - normal; &gt; 200 ms - violation of relaxation; 150-200 ms - pseudonormal type of left ventricular filling; &lt;150 ms - restrictive type of diastolic dysfunction IVRT (time of isovolumic relaxation of the left ventricl.) &lt;100 ms - normal; &gt; 100 ms - violation of relaxation</description>
          <units>ms.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>DT (Half-time of wave E)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="253" spread="52.7"/>
                    <measurement group_id="B2" value="257.6" spread="46.3"/>
                    <measurement group_id="B3" value="252.3" spread="55.1"/>
                    <measurement group_id="B4" value="254.7" spread="51.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVRT (time of isovolumic relaxation of the left ventriclar)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103.4" spread="11.1"/>
                    <measurement group_id="B2" value="106" spread="9.8"/>
                    <measurement group_id="B3" value="105.3" spread="13.9"/>
                    <measurement group_id="B4" value="104.7" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Echocardiography - 7. LVmass/ BSA (g/m^2)</title>
          <description>left ventricular mass (LVmass)/ body surface area (BSA) = left ventricular mass index (g/m^2).&#xD;
Men - normal - 115 g / m^2 Women - normal - 95 g / m^2</description>
          <units>g/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119.1" spread="29"/>
                    <measurement group_id="B2" value="152.8" spread="48"/>
                    <measurement group_id="B3" value="134.04" spread="32"/>
                    <measurement group_id="B4" value="135.3" spread="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Echocardiography - 8. RWT - relative wall thickness of the left ventricle.</title>
          <description>Calculated by the formula left ventricular posterior wall thickness + interventricular septal thickness / left ventricular end-diastolic size.&#xD;
RWT more 0.42 - concentric hypertrophy of the left ventricular myocardium. RWT less or equal 0.42 - eccentric left ventricular myocardial hypertrophy.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.44" spread="0.07"/>
                    <measurement group_id="B2" value="0.4" spread="0.07"/>
                    <measurement group_id="B3" value="0.4" spread="0.06"/>
                    <measurement group_id="B4" value="0.43" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Echocardiography - 9. Mitral regurgitation.</title>
          <description>The data at the time of hospitalization for routine CABG. Evaluation of the degree of Mitral regurgitation by echocardiography data.&#xD;
Assessment of the degree by the ratio of the area of the regurgitation stream to the area of the left atrium:&#xD;
Grade 1 (easy) - less than 20% Grade 2 (moderate) - 20-40% Grade 3 (severe) - more than 40% Valve insufficiency is absent in the norm. 2 degree of failure - requires dynamic observation. 3-4 degree of failure requires further examination, the decision of the HeartTeam about the need for surgical correction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Not</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 degree Mitral regurgitation.</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 degree Mitral regurgitation.</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 degree Mitral regurgitation.</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Echocardiography - 10. Tricuspid regurgitation.</title>
          <description>Criteria tricuspid regurgitation. Grade1-central jet area regurgitation&lt;5.0 cm^2, Vena contracta is minimal.Grade2-The area of central jet area regurgitation is 5.0-10cm^2, Vena contracta is &lt;0.7cm. Grade 3-central jet area regurgitation&gt;10cm^2, Vena contracta&gt;0.7cm Additional criterion - retrograde movement of blood in the hepatic vein during systole. Valve insufficiency is absent in the norm. 2degree of failure-requires dynamic observation. 3-4degree of failure requires further examination, the decision of the HeartTeam abCriteria tricuspid insufficiency out the need for surgical correction.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 degreeTricuspid regurgitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 degreeTricuspid regurgitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 degreeTricuspid regurgitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Echocardiography - 11. Aortic regurgitation.</title>
          <description>Evaluation of the degree of Aortic regurgitation by echocardiography data.&#xD;
Ultrasound criteria for the significance of aortic valve insufficiency are determined by the time of the half-decay of the diastolic gradient of the aortic regurgitation flow:&#xD;
1 stage more than 400 ms; 2 stage 250-400 ms; 3 degree less than 250ms Valve insufficiency is absent in the norm. 2 degree of failure - requires dynamic observation. 3-4 degree of failure requires further examination, the decision of the HeartTeam about the need for surgical correction.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 degree Aortic regurgitation.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 degree Aortic regurgitation.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 degree Aortic regurgitation.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Echocardiography - 12. Signs of myocardial remodeling.</title>
          <description>The data at the time of hospitalization for routine CABG</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Left ventricular diastolic function/</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left ventricular aneurysm.</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in local kinetics.</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of the Initial Risk of Surgery (EuroScore II).</title>
        <description>EuroScoreII is intended to assess the risk of adverse outcome of coronary artery bypass grafting. Assessment factors: age, sex, serum creatinine, extracardiac artery disease, chronic lung disease, severe neurological disorders, previous cardiac surgery, previous myocardial infarction, left ventricular dysfunction, diabetes mellitus, pulmonary hypertension, IV class of angina severity, active endocarditis, unstable angina, surgery, critical condition of the patient before surgery, type of surgery. The higher the percentage, the higher the risk of surgery.</description>
        <time_frame>Before CABG surgery at baseline.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of the Initial Risk of Surgery (EuroScore II).</title>
          <description>EuroScoreII is intended to assess the risk of adverse outcome of coronary artery bypass grafting. Assessment factors: age, sex, serum creatinine, extracardiac artery disease, chronic lung disease, severe neurological disorders, previous cardiac surgery, previous myocardial infarction, left ventricular dysfunction, diabetes mellitus, pulmonary hypertension, IV class of angina severity, active endocarditis, unstable angina, surgery, critical condition of the patient before surgery, type of surgery. The higher the percentage, the higher the risk of surgery.</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.68"/>
                    <measurement group_id="O2" value="1.07" spread="0.47"/>
                    <measurement group_id="O3" value="1.02" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Length of Hospital Stay. Length of Stay in the Intensive Care Unit.</title>
        <description>The results were obtained from the analysis of primary data.</description>
        <time_frame>Primary hospitalization for planned CABG.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.&#xD;
Сontrol group.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay. Length of Stay in the Intensive Care Unit.</title>
          <description>The results were obtained from the analysis of primary data.</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospital Stay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" spread="11.2"/>
                    <measurement group_id="O2" value="32.8" spread="13.9"/>
                    <measurement group_id="O3" value="38.4" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days in the intensive care unite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="2.2"/>
                    <measurement group_id="O2" value="3.1" spread="1.7"/>
                    <measurement group_id="O3" value="3.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Length of hospital stay.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Length of stay in the intensive care unit.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Severity of the Systemic Inflammatory Response in the Postoperative Period (Leukocytosis).</title>
        <description>Assessment of the severity of the systemic inflammatory response during hospital stay after surgery. Assessment of the level of inflammation by the severity of an increase in leukocytes (leukocytosis).&#xD;
Leukocytosis - an increase in the number of leukocytes per unit volume of blood. The norm of leukocytes in the blood is 5.5-8.810^9 /l. For adults, leukocytosis is considered to be an increase in the number of leukocytes in the blood of more than 9.0*10^9 / l In the statistical analysis, the grouping of indicators in the indicated intervals was used, in view of the individual characteristics of the course of the postoperative period in each case.</description>
        <time_frame>The parameters were evaluated initially at baseline in the postoperative period - an interval of 0-6 hours, 12-18 hours, 18-24 hours, 48 hours, 72 hours, 96 hours, 7 days and 14 days.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>The Severity of the Systemic Inflammatory Response in the Postoperative Period (Leukocytosis).</title>
          <description>Assessment of the severity of the systemic inflammatory response during hospital stay after surgery. Assessment of the level of inflammation by the severity of an increase in leukocytes (leukocytosis).&#xD;
Leukocytosis - an increase in the number of leukocytes per unit volume of blood. The norm of leukocytes in the blood is 5.5-8.810^9 /l. For adults, leukocytosis is considered to be an increase in the number of leukocytes in the blood of more than 9.0*10^9 / l In the statistical analysis, the grouping of indicators in the indicated intervals was used, in view of the individual characteristics of the course of the postoperative period in each case.</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>x10^9 cells/L&quot;</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leu (leukocytes) / initially</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="2.2"/>
                    <measurement group_id="O2" value="6.5" spread="1.5"/>
                    <measurement group_id="O3" value="7.3" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leu / in the postoperative period - an interval of 0-6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="6.3"/>
                    <measurement group_id="O2" value="14.1" spread="1.9"/>
                    <measurement group_id="O3" value="16.2" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leu / in the postoperative period - an interval of 12-18 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="3.99"/>
                    <measurement group_id="O2" value="14.7" spread="5.9"/>
                    <measurement group_id="O3" value="13.3" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leu / in the postoperative period - an interval of 18-24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.08" spread="2.4"/>
                    <measurement group_id="O2" value="15.4" spread="2.4"/>
                    <measurement group_id="O3" value="16.99" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leu / in the postoperative period 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="5.5"/>
                    <measurement group_id="O2" value="14.8" spread="2.2"/>
                    <measurement group_id="O3" value="13.3" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leu / in the postoperative period 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="4.1"/>
                    <measurement group_id="O2" value="9.4" spread="1.6"/>
                    <measurement group_id="O3" value="11.4" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leu / in the postoperative period 96 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="2.7"/>
                    <measurement group_id="O2" value="8.7" spread="2.6"/>
                    <measurement group_id="O3" value="10.4" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leu / in the postoperative period 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="5.9"/>
                    <measurement group_id="O2" value="9.5" spread="2.3"/>
                    <measurement group_id="O3" value="10.4" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leu / in the postoperative period 14 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="1.6"/>
                    <measurement group_id="O2" value="8.8" spread="1.7"/>
                    <measurement group_id="O3" value="10.4" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of leukocytes 0-6 hours of the postoperative period.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of leukocytes 12-18 hours of the postoperative period.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of leukocytes 18-24 hours of the postoperative period.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of leukocytes 48 hours of the postoperative period.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of leukocytes 72 hours of the postoperative period.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of leukocytes 96 hours of the postoperative period/</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of leukocytes 7 days of the postoperative period.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of leukocytes 14 days of the postoperative period.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of the Degree of General Inflammatory Response (C-reactive Protein (CRP)),</title>
        <description>Results of dynamic control of laboratory parameters of CRP. C-reactive protein. This fraction of plasma proteins increases in the presence of an inflammatory process in the body. It is synthesized in response to the ingestion of toxins of pathological microorganisms into the bloodstream and neutralizes them by binding them. In addition, it appears when the body's own cells are destroyed in the event of necrosis, tumor disintegration or extensive trauma, inactivating the resulting products. In addition to eliminating toxins, CRP triggers a cascade of immune responses aimed at eliminating pathologically altered structures.&#xD;
Normally absent (or less than 0.4 mg / l). In the statistical analysis, the grouping of indicators in the indicated intervals was used, in view of the individual characteristics of the course of the postoperative period in each case.</description>
        <time_frame>Initial data, control point in the interval 4-6 days of the postoperative period, control point in the interval 12-14 days of the postoperative period.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of the Degree of General Inflammatory Response (C-reactive Protein (CRP)),</title>
          <description>Results of dynamic control of laboratory parameters of CRP. C-reactive protein. This fraction of plasma proteins increases in the presence of an inflammatory process in the body. It is synthesized in response to the ingestion of toxins of pathological microorganisms into the bloodstream and neutralizes them by binding them. In addition, it appears when the body's own cells are destroyed in the event of necrosis, tumor disintegration or extensive trauma, inactivating the resulting products. In addition to eliminating toxins, CRP triggers a cascade of immune responses aimed at eliminating pathologically altered structures.&#xD;
Normally absent (or less than 0.4 mg / l). In the statistical analysis, the grouping of indicators in the indicated intervals was used, in view of the individual characteristics of the course of the postoperative period in each case.</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>mg/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CRP initially/ mg / l</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="6.05"/>
                    <measurement group_id="O2" value="3.05" spread="2"/>
                    <measurement group_id="O3" value="5.1" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP control point in the interval 4-6 days of the postoperative period/ mg/l</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2" spread="38"/>
                    <measurement group_id="O2" value="85.9" spread="51.8"/>
                    <measurement group_id="O3" value="121.1" spread="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP control point in the interval 12-14 days of the postoperative period/ mg/l</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="13.8"/>
                    <measurement group_id="O2" value="25.9" spread="20.9"/>
                    <measurement group_id="O3" value="24.4" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>CRP initially.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>CRP postoperative 4-6 days.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>CRP postoperative 12-14 days.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Volume of Discharge Through the Drains in the Early Postoperative Period.</title>
        <description>A daily assessment of the discharge by drainage before removal was carried out. It was carried out to assess the possible development of an excessive inflammatory reaction (polyserositis phenomena) in response to the transplantation of autologous bone marrow mononuclear cells.</description>
        <time_frame>Evaluation of these data - for the time spent in the intensive care unit before removing the drains.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>The Volume of Discharge Through the Drains in the Early Postoperative Period.</title>
          <description>A daily assessment of the discharge by drainage before removal was carried out. It was carried out to assess the possible development of an excessive inflammatory reaction (polyserositis phenomena) in response to the transplantation of autologous bone marrow mononuclear cells.</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>The volume of discharge through the drains on the first day after surgery.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541.2" spread="47.9"/>
                    <measurement group_id="O2" value="424" spread="95.7"/>
                    <measurement group_id="O3" value="410" spread="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The volume of discharge through the drains on the second day after the operation.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.7" spread="27.1"/>
                    <measurement group_id="O2" value="152" spread="54.2"/>
                    <measurement group_id="O3" value="195.4" spread="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The volume of discharge through the drains on the first day after surgery.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The volume of discharge through the drains on the second day after the operation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dynamics of Markers of Myocardial Damage (Troponin I, Myoglobin).</title>
        <description>Assessment of the severity of the period of ischemia / reperfusion. And the effect of autologous bone marrow mononuclear cells transplantation on these indicators.</description>
        <time_frame>1 and 3 days of the postoperative period.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Dynamics of Markers of Myocardial Damage (Troponin I, Myoglobin).</title>
          <description>Assessment of the severity of the period of ischemia / reperfusion. And the effect of autologous bone marrow mononuclear cells transplantation on these indicators.</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>mcg / l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Troponin I (postoperative day 1)/mcg / l</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.05" spread="18.9"/>
                    <measurement group_id="O2" value="5.7" spread="5.8"/>
                    <measurement group_id="O3" value="2.9" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin I (postoperative day 3)/mcg / l</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" spread="31.9"/>
                    <measurement group_id="O2" value="3.08" spread="3.7"/>
                    <measurement group_id="O3" value="1.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myoglobin postoperative day 1/mcg / l/</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="522.8" spread="711.6"/>
                    <measurement group_id="O2" value="385.6" spread="221.7"/>
                    <measurement group_id="O3" value="757.2" spread="1146.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myoglobin postoperative day 3/mcg / l</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" spread="1094.8"/>
                    <measurement group_id="O2" value="71.4" spread="41.4"/>
                    <measurement group_id="O3" value="70.4" spread="148.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Troponin I postoperative day 1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Troponin I postoperative day 3.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Myoglobin postoperative day 1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Myoglobin postoperative day 3.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dynamics of Markers of Myocardial Damage (Creatine Phosphokinase Fraction MB (CPK-MB)).</title>
        <description>Assessment of the severity of the period of ischemia / reperfusion. And the effect of autologous bone marrow mononuclear cells transplantation on these indicators.</description>
        <time_frame>1 and 3 days of the postoperative period.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Dynamics of Markers of Myocardial Damage (Creatine Phosphokinase Fraction MB (CPK-MB)).</title>
          <description>Assessment of the severity of the period of ischemia / reperfusion. And the effect of autologous bone marrow mononuclear cells transplantation on these indicators.</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>U/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CPK-MB postoperative day 1/ U/l</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3" spread="1024"/>
                    <measurement group_id="O2" value="63.02" spread="79.2"/>
                    <measurement group_id="O3" value="78.6" spread="136.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPK-MB postoperative day 3/ U/l</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="84.7"/>
                    <measurement group_id="O2" value="9.5" spread="9.3"/>
                    <measurement group_id="O3" value="4.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>CPK-MB postoperative day 1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>CPK-MB postoperative day 3.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intraoperative Assessment of Homeostasis (Hemoglobin (Hb).</title>
        <description>These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.</description>
        <time_frame>Intraoperative data.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Assessment of Homeostasis (Hemoglobin (Hb).</title>
          <description>These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>g/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hb intraoperatively before turning off the cardiopulmonary bypass (CPB).</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.05" spread="12.2"/>
                    <measurement group_id="O2" value="73.4" spread="8.08"/>
                    <measurement group_id="O3" value="75.8" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hb at the end of the operation.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3" spread="16.09"/>
                    <measurement group_id="O2" value="91.5" spread="8.6"/>
                    <measurement group_id="O3" value="86.7" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hb intraoperatively before turning off the cardiopulmonary bypass(CPB).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hb at the end of the operation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intraoperative Assessment of Homeostasis (Hematocrit (HCT)).</title>
        <description>These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.</description>
        <time_frame>Intraoperative data.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Assessment of Homeostasis (Hematocrit (HCT)).</title>
          <description>These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HCT intraoperatively before turning off the cardiopulmonary bypass(CPB).</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" spread="4.2"/>
                    <measurement group_id="O2" value="22.2" spread="1.9"/>
                    <measurement group_id="O3" value="23.2" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCT at the end of the operation.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" spread="5.2"/>
                    <measurement group_id="O2" value="27.8" spread="3.2"/>
                    <measurement group_id="O3" value="25.7" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>HCT intraoperatively before turning off the cardiopulmonary bypass (CPB).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>HCT at the end of the operation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intraoperative Assessment of Homeostasis (К+).</title>
        <description>These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.</description>
        <time_frame>Intraoperative data.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Assessment of Homeostasis (К+).</title>
          <description>These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>K+ intraoperatively before turning off the cardiopulmonary bypass(CPB).</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.01" spread="0.59"/>
                    <measurement group_id="O2" value="5.4" spread="0.9"/>
                    <measurement group_id="O3" value="4.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K+ at the end of the operation.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="0.4"/>
                    <measurement group_id="O2" value="4.5" spread="0.6"/>
                    <measurement group_id="O3" value="3.9" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>K+ intraoperatively before turning off the cardiopulmonary bypass (CPB).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>K+ at the end of the operation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cardiopulmonary Bypass Time.</title>
        <time_frame>Intraoperative data.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Bypass Time.</title>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135" spread="31.6"/>
                    <measurement group_id="O2" value="122.8" spread="19.7"/>
                    <measurement group_id="O3" value="144" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Aortic Clamping (Anoxia).</title>
        <description>Estimation of the time from the moment the clamp is applied to the aorta (complete clamping of the aorta) to the removal of the clamp from the aorta.</description>
        <time_frame>Intraoperative data.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Aortic Clamping (Anoxia).</title>
          <description>Estimation of the time from the moment the clamp is applied to the aorta (complete clamping of the aorta) to the removal of the clamp from the aorta.</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" spread="17.6"/>
                    <measurement group_id="O2" value="73.8" spread="22.3"/>
                    <measurement group_id="O3" value="84" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Complications in the Postoperative Period. Additional Estimation of Safety.</title>
        <description>The presence of complications in the postoperative period (Hydrothorax, Hydropericardium, Cardiac arrhythmias - atrial fibrillation / atrial flutter).</description>
        <time_frame>Postoperative period.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0.</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.&#xD;
Сontrol group.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Complications in the Postoperative Period. Additional Estimation of Safety.</title>
          <description>The presence of complications in the postoperative period (Hydrothorax, Hydropericardium, Cardiac arrhythmias - atrial fibrillation / atrial flutter).</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrothorax / postoperative period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hydropericardium / postoperative period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resternotomy / postoperative period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial fibrillation / postoperative period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial flutter / postoperative period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hydrothorax / postoperative period.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hydropericardium / postoperative period.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Resternotomy / postoperative period.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Atrial fibrillation / postoperative period.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Atrial flutter / postoperative period.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular Ejection Fraction - Echocardiography - Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment. Additional Estimation of Safety.</title>
        <description>Evaluation of myocardial contractility according to echocardiography, in particular the left ventricular ejection fraction, was carried out within 7-14 days of the postoperative period, depending on the patient's clinical condition, as well as the maximum degree of information content of this study. The lower the indicator, the worse the prognosis of an unfavorable outcome.</description>
        <time_frame>7-14 days of the postoperative period</time_frame>
        <population>all patients included in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction - Echocardiography - Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment. Additional Estimation of Safety.</title>
          <description>Evaluation of myocardial contractility according to echocardiography, in particular the left ventricular ejection fraction, was carried out within 7-14 days of the postoperative period, depending on the patient's clinical condition, as well as the maximum degree of information content of this study. The lower the indicator, the worse the prognosis of an unfavorable outcome.</description>
          <population>all patients included in the study</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.1" spread="1.6"/>
                    <measurement group_id="O2" value="56.4" spread="2.0"/>
                    <measurement group_id="O3" value="55.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment - Echocardiography (Size of the Left Ventricle - Index). Additional Estimation of Safety.</title>
        <description>Assessment of myocardial contractility according to echocardiography, in particular the size of the left ventricle - its index, was carried out within 7-14 days of the postoperative period, depending on the clinical condition of the patient, as well as on the maximum information content of this study. The higher the indicator (left ventricular size - index), the worse the prognosis of an unfavorable outcome.&#xD;
The index is used as an indicator of payment to obtain a more reliable result (taking into account the individual characteristics of each patient).&#xD;
index - left ventricular size (mm.)/ body mass index (kg/m^2).</description>
        <time_frame>7-14 days after surgery</time_frame>
        <population>All patients included in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.&#xD;
Сontrol group.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment - Echocardiography (Size of the Left Ventricle - Index). Additional Estimation of Safety.</title>
          <description>Assessment of myocardial contractility according to echocardiography, in particular the size of the left ventricle - its index, was carried out within 7-14 days of the postoperative period, depending on the clinical condition of the patient, as well as on the maximum information content of this study. The higher the indicator (left ventricular size - index), the worse the prognosis of an unfavorable outcome.&#xD;
The index is used as an indicator of payment to obtain a more reliable result (taking into account the individual characteristics of each patient).&#xD;
index - left ventricular size (mm.)/ body mass index (kg/m^2).</description>
          <population>All patients included in the study.</population>
          <units>mm/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lvd ind.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.08"/>
                    <measurement group_id="O2" value="3" spread="0.1"/>
                    <measurement group_id="O3" value="2.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lvs ind.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.07"/>
                    <measurement group_id="O2" value="2.1" spread="0.09"/>
                    <measurement group_id="O3" value="1.9" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LAind.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="0.06"/>
                    <measurement group_id="O2" value="2.2" spread="0.07"/>
                    <measurement group_id="O3" value="2.1" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Lvd ind. (Lvd mm./BSA kg / cm) - Evaluation of the left ventricular end-diastolic size index.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Lvs ind. (Lvs mm./BSA kg / cm) - Evaluation of the left ventricular end-systolic size index.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LAind. (LA mm./BSA kg / cm) - Left Atrial Size Index Assessment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of the Left Ventricle - Index - Echocardiography. Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment. Additional Estimation of Safety.</title>
        <description>Evaluation of myocardial contractility according to echocardiography, in particular volume of the left ventricle - index was carried out within 7-14 days of the postoperative period, depending on the patient's clinical condition, as well as the maximum degree of information content of this study. The greater the figure (volume of the left ventricle - index), the worse the prognosis of adverse outcome.&#xD;
The index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).&#xD;
index - volume of the left ventricle (ml.)/ body mass index (kg / m^2).</description>
        <time_frame>7-14 days after surgery</time_frame>
        <population>All patients included in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of the Left Ventricle - Index - Echocardiography. Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment. Additional Estimation of Safety.</title>
          <description>Evaluation of myocardial contractility according to echocardiography, in particular volume of the left ventricle - index was carried out within 7-14 days of the postoperative period, depending on the patient's clinical condition, as well as the maximum degree of information content of this study. The greater the figure (volume of the left ventricle - index), the worse the prognosis of adverse outcome.&#xD;
The index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).&#xD;
index - volume of the left ventricle (ml.)/ body mass index (kg / m^2).</description>
          <population>All patients included in the study</population>
          <units>mL/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LVEDV MOD BP ind</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" spread="4.8"/>
                    <measurement group_id="O2" value="70.9" spread="6.9"/>
                    <measurement group_id="O3" value="63.9" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVESV MOD BP ind.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" spread="3"/>
                    <measurement group_id="O2" value="31.9" spread="4.4"/>
                    <measurement group_id="O3" value="27.8" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LVEDV MOD BP ind. (LVEDV MOD BP ml./BSA kg / cm) - Evaluation of the left ventricular end-diastolic volume index.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evaluation of the left ventricular end-systolic volume index (LVESV MOD BP ind.)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Restoration of the Heart Rate After the Completion of the Main Stage of the Surgical Intervention. Additional Estimation of Safety.</title>
        <description>The need to perform defibrillation to restore sinus rhythm, at the end of the main stage of surgery.</description>
        <time_frame>Upon completion of the main stage of surgery.</time_frame>
        <population>All patients included in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Restoration of the Heart Rate After the Completion of the Main Stage of the Surgical Intervention. Additional Estimation of Safety.</title>
          <description>The need to perform defibrillation to restore sinus rhythm, at the end of the main stage of surgery.</description>
          <population>All patients included in the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality Associated With the Progression of Basic Disease.</title>
        <description>The total number of deaths - in the primary hospitalization and during the observation period of 12 months after surgical treatment - deaths associated with the progression of the initial disease.&#xD;
The complication rate for CABG operations is 30±10%. According to n1=kn2; n1 sample size, in the control. In group 0, k=2/3 times more than in group 1 and group 2. The difference between the test and control frequencies is ε=p1-p2. Accordingly, with p1 = 0.2; p2=0.4, δ= 0.1; n1=49.5, n2=33. The result is group 0 - 36, group 1 and 2 - 25+25 = 50. The null hypothesis of complication rate δ.All patients included in the study.</description>
        <time_frame>12 months after surgery</time_frame>
        <population>All patients included in the study (groups 1 and 2) were compared with the control group (Group 0).In patients included in study during the observation period after the treatment there was no progression of the underlying disease that was fatal.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.&#xD;
Сontrol group.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality Associated With the Progression of Basic Disease.</title>
          <description>The total number of deaths - in the primary hospitalization and during the observation period of 12 months after surgical treatment - deaths associated with the progression of the initial disease.&#xD;
The complication rate for CABG operations is 30±10%. According to n1=kn2; n1 sample size, in the control. In group 0, k=2/3 times more than in group 1 and group 2. The difference between the test and control frequencies is ε=p1-p2. Accordingly, with p1 = 0.2; p2=0.4, δ= 0.1; n1=49.5, n2=33. The result is group 0 - 36, group 1 and 2 - 25+25 = 50. The null hypothesis of complication rate δ.All patients included in the study.</description>
          <population>All patients included in the study (groups 1 and 2) were compared with the control group (Group 0).In patients included in study during the observation period after the treatment there was no progression of the underlying disease that was fatal.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life. Evaluation of the Quality of Life (Minnesota Questionnaire (MHFLQ), Seattle Questionnaire (SAQ), SF-36 Questionnaire). Estimation of Efficiency.</title>
        <description>The SF-36 questionnaire. The indicators of each scale vary between 0 and 100, where 100 represents total health. The results are presented in the form of scores on 8 scales, compiled in such a way that a higher score indicates a higher level of quality of life.MHFLQ - for patients with heart failure.The specified questionnaire consists of 21 questions. To answer each question, a scale of 6 points from the minimum intensity of certain symptoms to the maximum is used. The assessment is based on the sum of points, where the maximum number of points - 105 corresponds to the patient's worst condition. The lowest score 0 points is the best clinical condition of the patient. SAQ consists of 19 questions about the patient's condition, which are divided into the following 5 scales. The quality of life for each of the five scales under consideration is measured in percent, with 0% corresponding to the worst quality of life, and 100% to the best.</description>
        <time_frame>At baseline and after one year.</time_frame>
        <population>All patients included in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life. Evaluation of the Quality of Life (Minnesota Questionnaire (MHFLQ), Seattle Questionnaire (SAQ), SF-36 Questionnaire). Estimation of Efficiency.</title>
          <description>The SF-36 questionnaire. The indicators of each scale vary between 0 and 100, where 100 represents total health. The results are presented in the form of scores on 8 scales, compiled in such a way that a higher score indicates a higher level of quality of life.MHFLQ - for patients with heart failure.The specified questionnaire consists of 21 questions. To answer each question, a scale of 6 points from the minimum intensity of certain symptoms to the maximum is used. The assessment is based on the sum of points, where the maximum number of points - 105 corresponds to the patient's worst condition. The lowest score 0 points is the best clinical condition of the patient. SAQ consists of 19 questions about the patient's condition, which are divided into the following 5 scales. The quality of life for each of the five scales under consideration is measured in percent, with 0% corresponding to the worst quality of life, and 100% to the best.</description>
          <population>All patients included in the study.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning SF-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" spread="4.6"/>
                    <measurement group_id="O2" value="47.8" spread="6.2"/>
                    <measurement group_id="O3" value="51.1" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning SF-36 in year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9" spread="4"/>
                    <measurement group_id="O2" value="69.2" spread="5.4"/>
                    <measurement group_id="O3" value="68.6" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical Functioning SF-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="6.2"/>
                    <measurement group_id="O2" value="20.8" spread="8.4"/>
                    <measurement group_id="O3" value="21" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical Functioning SF-36 in year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" spread="7.4"/>
                    <measurement group_id="O2" value="41.7" spread="10"/>
                    <measurement group_id="O3" value="43.06" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain SF-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" spread="4.9"/>
                    <measurement group_id="O2" value="53.3" spread="6.7"/>
                    <measurement group_id="O3" value="57.8" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain SF-36 in year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" spread="4.5"/>
                    <measurement group_id="O2" value="75.8" spread="6.04"/>
                    <measurement group_id="O3" value="73.4" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health SF-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" spread="2.5"/>
                    <measurement group_id="O2" value="50.1" spread="3.4"/>
                    <measurement group_id="O3" value="45" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health SF-36 in year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" spread="2.4"/>
                    <measurement group_id="O2" value="53.2" spread="3.3"/>
                    <measurement group_id="O3" value="53.5" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality SF-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" spread="3.7"/>
                    <measurement group_id="O2" value="54.7" spread="4.9"/>
                    <measurement group_id="O3" value="53.8" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality SF-36 in year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3" spread="2.6"/>
                    <measurement group_id="O2" value="67.2" spread="3.6"/>
                    <measurement group_id="O3" value="64.7" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning SF-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4" spread="4.2"/>
                    <measurement group_id="O2" value="65.9" spread="5.7"/>
                    <measurement group_id="O3" value="66.3" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning SF-36 in year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" spread="3.9"/>
                    <measurement group_id="O2" value="77.08" spread="5.2"/>
                    <measurement group_id="O3" value="82.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role- Emotional SF-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" spread="7.2"/>
                    <measurement group_id="O2" value="40.7" spread="9.7"/>
                    <measurement group_id="O3" value="38.3" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role- Emotional SF-36 in year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" spread="7.6"/>
                    <measurement group_id="O2" value="53.7" spread="10.2"/>
                    <measurement group_id="O3" value="55.5" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health SF-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6" spread="3.1"/>
                    <measurement group_id="O2" value="64.9" spread="4.2"/>
                    <measurement group_id="O3" value="67.5" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health SF-36 in year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.5" spread="2.9"/>
                    <measurement group_id="O2" value="70" spread="3.98"/>
                    <measurement group_id="O3" value="72.7" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minnesota Quality of Life (MHFLQ)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" spread="3.6"/>
                    <measurement group_id="O2" value="35.1" spread="4.9"/>
                    <measurement group_id="O3" value="33.3" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minnesota Quality of Life (MHFLQ) in year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="2.9"/>
                    <measurement group_id="O2" value="22.7" spread="3.9"/>
                    <measurement group_id="O3" value="22.1" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seattle QuestionnairePhysical limitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" spread="3.5"/>
                    <measurement group_id="O2" value="42.6" spread="5.4"/>
                    <measurement group_id="O3" value="40" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SeattleQuestionnairePhysical limitation / in year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5" spread="2.9"/>
                    <measurement group_id="O2" value="60.8" spread="4.4"/>
                    <measurement group_id="O3" value="58.6" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SeattleQuestionnaireAngina stability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5" spread="6.3"/>
                    <measurement group_id="O2" value="40.4" spread="9.7"/>
                    <measurement group_id="O3" value="61" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SeattleQuestionnaireAngina stability / in year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" spread="7.1"/>
                    <measurement group_id="O2" value="91.9" spread="10.9"/>
                    <measurement group_id="O3" value="98.2" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SeattleQuestionnaireAngina frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7" spread="5.7"/>
                    <measurement group_id="O2" value="48.5" spread="8.8"/>
                    <measurement group_id="O3" value="46.07" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SeattleQuestionnaiAngina frequency / in year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3" spread="4.2"/>
                    <measurement group_id="O2" value="90.8" spread="6.6"/>
                    <measurement group_id="O3" value="86.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SeattleQuestionnaireTreatment satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" spread="3.7"/>
                    <measurement group_id="O2" value="72.1" spread="5.8"/>
                    <measurement group_id="O3" value="69.6" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SeattleQuestionnaireTreatmentSatisfaction/ in year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" spread="3.2"/>
                    <measurement group_id="O2" value="81.3" spread="4.9"/>
                    <measurement group_id="O3" value="80.4" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SeattleQuestionnaire Disease perception</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" spread="4.3"/>
                    <measurement group_id="O2" value="36.5" spread="6.7"/>
                    <measurement group_id="O3" value="37.9" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SeattleQuestionnaire Disease perception/ in year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7" spread="24.4"/>
                    <measurement group_id="O2" value="64.2" spread="20.8"/>
                    <measurement group_id="O3" value="64.3" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Functioning SF-36. Comparison of patients of group 1 and group 2 with the control group - group 0.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Role-Physical Functioning SF-36</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Bodily pain SF-36</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>General Health SF-36.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vitality SF-36.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Social Functioning SF-36.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Role- Emotional SF-36.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Health SF-36.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Minnesota Quality of Life (MHFLQ).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Seattle QuestionnairePhysical limitation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>SeattleQuestionnaireAngina stability.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>SeattleQuestionnaireAngina frequency.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>SeattleQuestionnaireTreatment satisfaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>SeattleQuestionnaire Disease perception.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of the Functional Class of Exertional Angina at 12 Months After Surgical Treatment.</title>
        <description>functional class - The usual load does not cause changes in the state of health. Painful attacks occur against the background of excessive loads - after climbing several flights of stairs, while walking fast.&#xD;
functional class - Pain attacks when walking more than 500 meters, when climbing stairs more than one floor.&#xD;
functional class - The patient does not tolerate minimal physical activity. An attack occurs when walking a distance of 50-100 meters. Climbing stairs is difficult.&#xD;
functional class - Activity is significantly limited. Angina pectoris manifests itself when performing minimal actions, including at rest.</description>
        <time_frame>up to 12 months</time_frame>
        <population>Data analysis of all patients underwent follow-up examination 12 months after surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of the Functional Class of Exertional Angina at 12 Months After Surgical Treatment.</title>
          <description>functional class - The usual load does not cause changes in the state of health. Painful attacks occur against the background of excessive loads - after climbing several flights of stairs, while walking fast.&#xD;
functional class - Pain attacks when walking more than 500 meters, when climbing stairs more than one floor.&#xD;
functional class - The patient does not tolerate minimal physical activity. An attack occurs when walking a distance of 50-100 meters. Climbing stairs is difficult.&#xD;
functional class - Activity is significantly limited. Angina pectoris manifests itself when performing minimal actions, including at rest.</description>
          <population>Data analysis of all patients underwent follow-up examination 12 months after surgery.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 functional class of angina pectoris1 year after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 functional class of angina pectoris1 year after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 functional class of angina pectoris1 year after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 functional class of angina pectoris1 year after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dynamics of the Functional Class of Heart Failure (NYHA). Estimation of Efficiency.</title>
        <description>functional class - There is no limitation of a person's physical activity, shortness of breath manifests itself when going above the third floor.&#xD;
functional class - slight limitation of activity, palpitations, shortness of breath, fatigue occur during normal physical activity and more.&#xD;
functional class - Symptoms occur with the smallest physical activity, resulting in a significant decrease in activity. At rest, clinical manifestations are not observed.&#xD;
The smaller the functional class, the better the quality of human life.</description>
        <time_frame>Assessment of the dynamics at 12 months after treatment.</time_frame>
        <population>In one case, a patient of Groups 1 through 12 months after the treatment, marked progression of the functional class of heart failure. It should be noted that this patient did not adhere to the recommendations on lifestyle and drug therapy in the postoperative period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Coronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Dynamics of the Functional Class of Heart Failure (NYHA). Estimation of Efficiency.</title>
          <description>functional class - There is no limitation of a person's physical activity, shortness of breath manifests itself when going above the third floor.&#xD;
functional class - slight limitation of activity, palpitations, shortness of breath, fatigue occur during normal physical activity and more.&#xD;
functional class - Symptoms occur with the smallest physical activity, resulting in a significant decrease in activity. At rest, clinical manifestations are not observed.&#xD;
The smaller the functional class, the better the quality of human life.</description>
          <population>In one case, a patient of Groups 1 through 12 months after the treatment, marked progression of the functional class of heart failure. It should be noted that this patient did not adhere to the recommendations on lifestyle and drug therapy in the postoperative period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 functional class heart failure (NYHA).</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 functional class heart failure (NYHA).</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 functional class heart failure (NYHA).</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Left Ventricular Ejection Fraction 12 Months After Treatment.</title>
        <description>According to echocardiography.</description>
        <time_frame>12 months after treatment.</time_frame>
        <population>All patients included in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Left Ventricular Ejection Fraction 12 Months After Treatment.</title>
          <description>According to echocardiography.</description>
          <population>All patients included in the study.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.4" spread="1.5"/>
                    <measurement group_id="O2" value="58.1" spread="1.8"/>
                    <measurement group_id="O3" value="58.4" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimation of the Index of Linear Parameters of the Left Ventricle 12 Months After the Treatment. Estimation of Efficiency.</title>
        <description>Evaluation of myocardial contractility according to echocardiography, in particular the size of the left ventricle - the index was carried out 12 months after CABG. The higher the indicator (left ventricular size - index), the worse the prognosis of an unfavorable outcome.&#xD;
The index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).&#xD;
index - size of the left ventricle (mm.)/ body mass index (kg/m^2).</description>
        <time_frame>12 months after the treatment.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimation of the Index of Linear Parameters of the Left Ventricle 12 Months After the Treatment. Estimation of Efficiency.</title>
          <description>Evaluation of myocardial contractility according to echocardiography, in particular the size of the left ventricle - the index was carried out 12 months after CABG. The higher the indicator (left ventricular size - index), the worse the prognosis of an unfavorable outcome.&#xD;
The index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).&#xD;
index - size of the left ventricle (mm.)/ body mass index (kg/m^2).</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>mm/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lvd ind.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.07"/>
                    <measurement group_id="O2" value="2.9" spread="0.08"/>
                    <measurement group_id="O3" value="2.8" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lvs ind.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.06"/>
                    <measurement group_id="O2" value="2.07" spread="0.08"/>
                    <measurement group_id="O3" value="1.8" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LAind.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.05"/>
                    <measurement group_id="O2" value="2.3" spread="0.07"/>
                    <measurement group_id="O3" value="2.2" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Lvd ind. (Lvd mm./BSA) - left ventricular end-diastolic size index. All patients included in the study.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Lvs ind. (Lvs mm./BSA kg / cm) - left ventricular end-systolic size index.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LAind. (LA mm./BSA kg / cm) - left atrial index.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimation of the Index of Volumetric Parameters of the Left Ventricle 12 Months After the Treatment. Estimation of Efficiency.</title>
        <description>Evaluation of myocardial contractility according to echocardiography, in particular the volume of the left ventricle - the index was carried out 12 months after CABG. The higher the indicator (left ventricular volume - index), the worse the prognosis of an unfavorable outcome.&#xD;
The index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).&#xD;
index - volume of the left ventricle (mm.)/ body mass index (kg/m^2).</description>
        <time_frame>12 Months After the Treatment</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Coronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimation of the Index of Volumetric Parameters of the Left Ventricle 12 Months After the Treatment. Estimation of Efficiency.</title>
          <description>Evaluation of myocardial contractility according to echocardiography, in particular the volume of the left ventricle - the index was carried out 12 months after CABG. The higher the indicator (left ventricular volume - index), the worse the prognosis of an unfavorable outcome.&#xD;
The index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).&#xD;
index - volume of the left ventricle (mm.)/ body mass index (kg/m^2).</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>mL/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LVEDV MOD BP ind.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3" spread="4.4"/>
                    <measurement group_id="O2" value="70.4" spread="6.2"/>
                    <measurement group_id="O3" value="66.9" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVESV MOD BP ind.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="2.6"/>
                    <measurement group_id="O2" value="31.5" spread="3.9"/>
                    <measurement group_id="O3" value="25.6" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LVEDV MOD BP ind. (LVEDV MOD BP ml./BSA kg / cm) - left ventricular end-diastolic volume index.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LVESV MOD BP ind. (LVESV MOD BP ml./BSA kg / cm) - left ventricular end-systolic volume index.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Left Ventricular Diastolic Function - Peak E of Transmitral Flow and Peak А of Transmitral Flow 12 Months After Treatment.</title>
        <description>Evaluation of left ventricular diastolic function (echocardiography). The peak velocity E reflects the pressure gradient between the LA and LV in early diastole, and it is affected by preload and disturbance LV relaxation The speed of peak A, which forms at the end diastole, influences LV compliance and contractility left atrium.</description>
        <time_frame>12 months after treatment.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Left Ventricular Diastolic Function - Peak E of Transmitral Flow and Peak А of Transmitral Flow 12 Months After Treatment.</title>
          <description>Evaluation of left ventricular diastolic function (echocardiography). The peak velocity E reflects the pressure gradient between the LA and LV in early diastole, and it is affected by preload and disturbance LV relaxation The speed of peak A, which forms at the end diastole, influences LV compliance and contractility left atrium.</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>meters/sec.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peak E of transmitral flow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.04"/>
                    <measurement group_id="O2" value="0.7" spread="0.05"/>
                    <measurement group_id="O3" value="0.8" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak А of transmitral flow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.09"/>
                    <measurement group_id="O2" value="07" spread="0.1"/>
                    <measurement group_id="O3" value="0.8" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Peak E of transmitral flow</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Peak A of transmitral flow.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Left Ventricular Diastolic Function E/A - 12 Months After Treatment.</title>
        <description>The ratio of the transmitral flow, wave E (ejection wave / left ventricular contraction) to wave A (ejection wave / left atrial contraction). The norm is 0.75-1.5 Less than 0.75 violation of relaxation, more than 1.5 restrictive type of diastolic dysfunction.</description>
        <time_frame>12 months after treatment</time_frame>
        <population>All patients included in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Left Ventricular Diastolic Function E/A - 12 Months After Treatment.</title>
          <description>The ratio of the transmitral flow, wave E (ejection wave / left ventricular contraction) to wave A (ejection wave / left atrial contraction). The norm is 0.75-1.5 Less than 0.75 violation of relaxation, more than 1.5 restrictive type of diastolic dysfunction.</description>
          <population>All patients included in the study.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.1"/>
                    <measurement group_id="O2" value="1.2" spread="0.1"/>
                    <measurement group_id="O3" value="1.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Peak E of transmitral flow/ Peak A of transmitral flow (E/A).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Left Ventricular Diastolic Function - DT and IVRT 12 Months After Treatment.</title>
        <description>Echocardiographic data ( DT (Half-time of wave E), time of isovolumic relaxation of the left ventricle (IVRT).&#xD;
DT (Half-time of wave E). The DT time index reflects the relaxation process LV, LV diastolic pressure after mitral valve opening, and LV compliance. 150-200 ms - normal; &gt; 200 ms - violation of relaxation; 150-200 ms - pseudonormal type of left ventricular filling; &lt;150 ms - restrictive type of diastolic dysfunction IVRT (time of isovolumic relaxation of the left ventricl.) &lt;100 ms - normal; &gt; 100 ms - violation of relaxation</description>
        <time_frame>12 Months After Treatment.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Left Ventricular Diastolic Function - DT and IVRT 12 Months After Treatment.</title>
          <description>Echocardiographic data ( DT (Half-time of wave E), time of isovolumic relaxation of the left ventricle (IVRT).&#xD;
DT (Half-time of wave E). The DT time index reflects the relaxation process LV, LV diastolic pressure after mitral valve opening, and LV compliance. 150-200 ms - normal; &gt; 200 ms - violation of relaxation; 150-200 ms - pseudonormal type of left ventricular filling; &lt;150 ms - restrictive type of diastolic dysfunction IVRT (time of isovolumic relaxation of the left ventricl.) &lt;100 ms - normal; &gt; 100 ms - violation of relaxation</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DT (Half-time of wave E).</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.4" spread="15.2"/>
                    <measurement group_id="O2" value="252.6" spread="20.08"/>
                    <measurement group_id="O3" value="256.6" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>time of isovolumic relaxation of the left ventricle (IVRT).</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9" spread="4.1"/>
                    <measurement group_id="O2" value="102.4" spread="5.5"/>
                    <measurement group_id="O3" value="99.6" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>DT (Half-time of wave E).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>time of isovolumic relaxation of the left ventricle</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9</p_value>
            <method>RepeatedMeasures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distance Traveled in the 6-minute Walk Test. Test Results With 6 Minute Walk</title>
        <description>The dynamic of the number of meters walked according to the 6-minutes walk test (6MWD) in the observation groups.</description>
        <time_frame>initially and after 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
        </group_list>
        <measure>
          <title>Distance Traveled in the 6-minute Walk Test. Test Results With 6 Minute Walk</title>
          <description>The dynamic of the number of meters walked according to the 6-minutes walk test (6MWD) in the observation groups.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Original number of meters.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.06" spread="17.6"/>
                    <measurement group_id="O2" value="319.8" spread="24.5"/>
                    <measurement group_id="O3" value="329.9" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of meters in 12 months.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="433.54" spread="20.6"/>
                    <measurement group_id="O2" value="524.4" spread="28.7"/>
                    <measurement group_id="O3" value="452.7" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0367</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Functioning Grafts 12 Months After CABG. Patency of Grafts Within a Specified Time of Treatment (Angiography).</title>
        <description>According to the angiographic study.</description>
        <time_frame>up to 12 months</time_frame>
        <population>All patients included in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Functioning Grafts 12 Months After CABG. Patency of Grafts Within a Specified Time of Treatment (Angiography).</title>
          <description>According to the angiographic study.</description>
          <population>All patients included in the study.</population>
          <units>Number of grafts</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial number of grafts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of functioning grafts at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of non-functioning grafts after 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Assessment of the functioning of grafts. Patency of grafts within a specified time of treatment (angiography).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of the Effect of Left Ventricular Diastolic Dysfunction on the Patency of the Grafts.</title>
        <description>Echocardiographic data.</description>
        <time_frame>up to 12 months</time_frame>
        <population>All patients included in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Intramyocardial Administration 0.9 % NaCl (Sodium Chloride) - Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Intramyocardial Administration Autologous Bone Marrow Stem Cells - Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Intramyocardial and Intracoronary Administration Autologous Bone Marrow Stem Cells - Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of the Effect of Left Ventricular Diastolic Dysfunction on the Patency of the Grafts.</title>
          <description>Echocardiographic data.</description>
          <population>All patients included in the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with non-functioning grafts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with non-functioning grafts in the presence of LV diastolic dysfunction after 12 months.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Volume of Cellular Material (Cytosis).</title>
        <description>Dependence and Duration of Positive Clinical Effect on the Amount of Injected Cell Material (cytosis).</description>
        <time_frame>Initial data at the time of collection of bone marrow cells.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial ( 0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow mononuclear cells.</description>
          </group>
        </group_list>
        <measure>
          <title>The Volume of Cellular Material (Cytosis).</title>
          <description>Dependence and Duration of Positive Clinical Effect on the Amount of Injected Cell Material (cytosis).</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>*10^8cells/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" spread="8.9"/>
                    <measurement group_id="O2" value="20.3" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Discriminant Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Amount of Cell Material (Percentage).</title>
        <description>Dependence and duration of positive clinical effect on the amount of injected cell material (Mononuclear fraction %, CD34+ %, CD133+ %).&#xD;
Assessment - mononuclear fraction, CD 34 +, CD 133+ according to flow cytometry data.</description>
        <time_frame>Initial data at the time of collection of bone marrow cells.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
        </group_list>
        <measure>
          <title>The Amount of Cell Material (Percentage).</title>
          <description>Dependence and duration of positive clinical effect on the amount of injected cell material (Mononuclear fraction %, CD34+ %, CD133+ %).&#xD;
Assessment - mononuclear fraction, CD 34 +, CD 133+ according to flow cytometry data.</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mononuclear fraction/ %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.04" spread="2.9"/>
                    <measurement group_id="O2" value="20.0" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD34+/ %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.22"/>
                    <measurement group_id="O2" value="1.18" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD133+/ %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.08"/>
                    <measurement group_id="O2" value="0.38" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mononuclear fraction %</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Discriminant Analysis</method>
            <method_desc>Data were analyzed by 1, 2, and 3 sections according to the study design.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD34+ %</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>Discriminant Analysis</method>
            <method_desc>Data were analyzed by 1, 2, and 3 sections according to the study design.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD133+ %</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Discriminant Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Smoking as a Factor That Negatively Affects the Results of the Test With a 6-minute Walk in Dynamics.</title>
        <description>The distance covered (in meters) was compared with the proper value depending on age (years), height (cm), weight (kg), body mass index (BMI). The due values (6MWD (i)) were calculated using the following formulas: For men: 6МWD (i) = 7.57 × height - 5.02 × age - 1.76 × weight - 309 or 6MWD (i) = 1140 - 5.61 × BMI - 6.94 × age. For women:&#xD;
6МWD (i) = 2.11 × height - 2.29 × weight - 5.78 × age + 667 Or 6МWD (i) = 1017 - 6.24 × BMI - 5.83 × age. This difference at baseline is reported as distance walked for smokers minus non-smokers.</description>
        <time_frame>12 months after treatment.</time_frame>
        <population>The data of all patients initially included in the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 0</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>Сoronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Сoronary artery bypass grafting with intramyocardial ( 0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow mononuclear cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Smoking as a Factor That Negatively Affects the Results of the Test With a 6-minute Walk in Dynamics.</title>
          <description>The distance covered (in meters) was compared with the proper value depending on age (years), height (cm), weight (kg), body mass index (BMI). The due values (6MWD (i)) were calculated using the following formulas: For men: 6МWD (i) = 7.57 × height - 5.02 × age - 1.76 × weight - 309 or 6MWD (i) = 1140 - 5.61 × BMI - 6.94 × age. For women:&#xD;
6МWD (i) = 2.11 × height - 2.29 × weight - 5.78 × age + 667 Or 6МWD (i) = 1017 - 6.24 × BMI - 5.83 × age. This difference at baseline is reported as distance walked for smokers minus non-smokers.</description>
          <population>The data of all patients initially included in the study were analyzed.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>diference between smokers and non-smoking participants at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230.04" spread="28.7"/>
                    <measurement group_id="O2" value="215.3" spread="31.4"/>
                    <measurement group_id="O3" value="224.8" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diference between baseline and1 year after surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.9" spread="4.9"/>
                    <measurement group_id="O2" value="8.5" spread="2.7"/>
                    <measurement group_id="O3" value="62.1" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factor analysis - determining the influence of a factor, in this case, smoking, on the deficit in the number of meters passed according to the test with a 6-minute walk.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.046</p_value>
            <method>Factor analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months after treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 0</title>
          <description>Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
        </group>
        <group group_id="E2">
          <title>Group 1</title>
          <description>Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.</description>
        </group>
        <group group_id="E3">
          <title>Group 2</title>
          <description>Coronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations identified.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vladimir V Komok, Ph.D</name_or_title>
      <organization>First Pavlov State Medical University of St. Petersburg</organization>
      <phone>8-904-632-19-00</phone>
      <email>vladimir_komok@mail.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

